<p>儘管 <strong>Cawachi Limited</strong>（東京證券交易所代碼：2664）上週的財報數據良好，但市場似乎對此反應平平。我們進行了一些分析，試圖找出原因，並認為投資者可能忽視了財報中一些令人鼓舞的因素。</p>
<p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行研發。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5478544-earnings-and-revenue-history-1-dark-2/1762379223725?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5478544-earnings-and-revenue-history-1-dark-2/1762379223725"/></p>
<p>東京證券交易所：2664 財報和收入歷史 2025 年 11 月 5 日</p>
<h2>非常規項目對利潤的影響</h2>
<p>重要的是，我們的數據表明，Cawachi 去年的利潤因非常規項目減少了 12 億日元。雖然由於非常規項目的扣除在第一時間令人失望，但也有積極的一面。我們查看了數千家上市公司，發現非常規項目通常是一次性的。而且，畢竟，這正是會計術語所暗示的。假設這些非常規支出不會再次出現，我們因此預計 Cawachi 明年的利潤會更高，其他條件不變。</p>
<p><strong>注意：</strong> 我們始終建議投資者檢查資產負債表的強度。點擊這裏查看我們對 Cawachi 的資產負債表分析。</p>
<h2>我們對 Cawachi 利潤表現的看法</h2>
<p>非常規項目（支出）在過去一年中削弱了 Cawachi 的收益，但我們可能會在明年看到改善。基於這一觀察，我們認為 Cawachi 的法定利潤實際上低估了其盈利潛力！而且過去三年每股收益年增長 5.5%。當然，在分析其收益時，我們才剛剛開始；還可以考慮利潤率、預測增長和投資回報等其他因素。如果你想更深入地瞭解 Cawachi，還需要關注它目前面臨的風險。為此，我們發現了 <strong>2 個警示信號</strong>（其中 1 個不容忽視！），在購買 Cawachi 的任何股票之前，你應該瞭解這些。</p>
<p>這份報告僅關注了一個因素，揭示了 Cawachi 利潤的性質。但如果你能夠專注於細節，總會有更多的發現。有些人認為高股本回報率是優質企業的良好標誌。因此，你可能希望查看這份 <strong>免費</strong> 的高股本回報率公司集合，或這份高內部持股的股票列表。</p>

2664

<p>Cawachi Limited（東京證券交易所代碼：2664）報告了令人鼓舞的收益，但市場反應卻平淡。分析師建議，投資者可能會忽視收益報告中的積極方面，特別是一些異常支出對利潤造成了 12 億日元的影響。這些異常項目通常是一次性事件，表明明年利潤有改善的潛力。儘管面臨挑戰，Cawachi 的每股收益在過去三年中年均增長 5.5%，顯示出其潛在的實力。然而，投資者在考慮 Cawachi 的股票之前，應注意兩個警示信號</p>

<p>The market seemed underwhelmed by last week's earnings announcement from <strong>Cawachi Limited</strong> (TSE:2664) despite the healthy numbers. We did some analysis to find out why and believe that investors might be missing some encouraging factors contained in the earnings.</p>
<div class="lb-trans"><p>儘管 <strong>Cawachi Limited</strong>（東京證券交易所代碼：2664）上週的財報數據良好，但市場似乎對此反應平平。我們進行了一些分析，試圖找出原因，並認為投資者可能忽視了財報中一些令人鼓舞的因素。</p>
</div><p>AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.</p>
<div class="lb-trans"><p>人工智能即將改變醫療保健。這 20 只股票正在從早期診斷到藥物發現等各個方面進行研發。最棒的是——它們的市值都在 100 億美元以下——現在仍然有機會提前佈局。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/5478544-earnings-and-revenue-history-1-dark-2/1762379223725" alt="" original-src="https://images.simplywall.st/asset/chart/5478544-earnings-and-revenue-history-1-dark-2/1762379223725"/></p>
<p>TSE:2664 Earnings and Revenue History November 5th 2025</p>
<div class="lb-trans"><p>東京證券交易所：2664 財報和收入歷史 2025 年 11 月 5 日</p>
</div><h2>The Impact Of Unusual Items On Profit</h2>
<div class="lb-trans"><h2>非常規項目對利潤的影響</h2>
</div><p>Importantly, our data indicates that Cawachi's profit was reduced by JP¥1.2b, due to unusual items, over the last year. While deductions due to unusual items are disappointing in the first instance, there is a silver lining. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Cawachi to produce a higher profit next year, all else being equal.</p>
<div class="lb-trans"><p>重要的是，我們的數據表明，Cawachi 去年的利潤因非常規項目減少了 12 億日元。雖然由於非常規項目的扣除在第一時間令人失望，但也有積極的一面。我們查看了數千家上市公司，發現非常規項目通常是一次性的。而且，畢竟，這正是會計術語所暗示的。假設這些非常規支出不會再次出現，我們因此預計 Cawachi 明年的利潤會更高，其他條件不變。</p>
</div><p><strong>Note:</strong> we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Cawachi.</p>
<div class="lb-trans"><p><strong>注意：</strong> 我們始終建議投資者檢查資產負債表的強度。點擊這裏查看我們對 Cawachi 的資產負債表分析。</p>
</div><h2>Our Take On Cawachi's Profit Performance</h2>
<div class="lb-trans"><h2>我們對 Cawachi 利潤表現的看法</h2>
</div><p>Unusual items (expenses) detracted from Cawachi's earnings over the last year, but we might see an improvement next year. Based on this observation, we consider it likely that Cawachi's statutory profit actually understates its earnings potential! And the EPS is up 5.5% annually, over the last three years. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you want to do dive deeper into Cawachi, you'd also look into what risks it is currently facing. To help with this, we've discovered <strong>2 warning signs</strong> (1 shouldn't be ignored!) that you ought to be aware of before buying any shares in Cawachi.</p>
<div class="lb-trans"><p>非常規項目（支出）在過去一年中削弱了 Cawachi 的收益，但我們可能會在明年看到改善。基於這一觀察，我們認為 Cawachi 的法定利潤實際上低估了其盈利潛力！而且過去三年每股收益年增長 5.5%。當然，在分析其收益時，我們才剛剛開始；還可以考慮利潤率、預測增長和投資回報等其他因素。如果你想更深入地瞭解 Cawachi，還需要關注它目前面臨的風險。為此，我們發現了 <strong>2 個警示信號</strong>（其中 1 個不容忽視！），在購買 Cawachi 的任何股票之前，你應該瞭解這些。</p>
</div><p>This note has only looked at a single factor that sheds light on the nature of Cawachi's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this <strong>free</strong> collection of companies boasting high return on equity, or this list of stocks with high insider ownership.</p>
<div class="lb-trans"><p>這份報告僅關注了一個因素，揭示了 Cawachi 利潤的性質。但如果你能夠專注於細節，總會有更多的發現。有些人認為高股本回報率是優質企業的良好標誌。因此，你可能希望查看這份 <strong>免費</strong> 的高股本回報率公司集合，或這份高內部持股的股票列表。</p>
</div>

Cawachi（TSE:2664）的收益似乎前景可期